Your session is about to expire
← Back to Search
WTX-124 + Pembrolizumab for Solid Tumors
Study Summary
This trial is testing a new drug, WTX-124, as a possible treatment for advanced solid tumors. WTX-124 will be given alone and in combination with another drug, pembrolizumab, to see if it is safe and effective.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2024 Phase 2 trial • 57 Patients • NCT03004183Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My organs and bone marrow are functioning well.I need steroids for my brain cancer symptoms.I am fully active or can carry out light work.I do not have an ongoing serious infection.I have an immune system disorder or am on medication that weakens my immune system.I have previously received IL-2 therapy.I have not received a live vaccine within the last 30 days.I have received a transplant from another person.I have not had major surgery in the last 2 weeks.I had radiotherapy less than 2 weeks ago, except for short-term palliative care.My solid tumor is eligible for CPI treatment like anti-PD-(L)1.I agree to use effective birth control during and for 4 months after treatment.I agree to have biopsies before and during treatment.I do not have an active hepatitis C infection.I haven't had another active cancer in the past 2 years, except for certain low-risk types or localized cancers considered cured.I have been treated for an autoimmune disease in the last 2 years.I am 18 years old or older.I do not have an active hepatitis B infection.I don't have severe side effects from past treatments, except for hair loss or mild nerve pain from platinum-based therapy.I have at least one tumor that can be measured.I haven't taken any experimental cancer drugs or treatments within the last 4 weeks.I have a serious heart condition.I have or had lung inflammation that needed steroids.I am HIV-positive and have had Kaposi sarcoma or Multicentric Castleman Disease.
- Group 1: WTX-124 in combination with pembrolizumab dose expansion in advanced or metastatic RCC
- Group 2: WTX-124 monotherapy dose escalation
- Group 3: WTX-124 monotherapy dose expansion in advanced or metastatic cutaneous malignant melanoma
- Group 4: WTX-124 monotherapy dose expansion in advanced or metastatic RCC
- Group 5: WTX-124 in combo with pembro dose expansion in advanced/metastatic cutaneous malignant melanoma
- Group 6: WTX-124 in combination with pembrolizumab dose escalation
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has the FDA sanctioned WTX-124 for use?
"Our team at Power gave WTX-124 a score of 1 on the safety scale, as this is still an early stage trial with limited evidence regarding efficacy and safety."
Are there any vacancies open for prospective participants in this clinical trial?
"Affirmative. The data hosted on clinicaltrials.gov suggests that this trial is presently searching for participants and was initially posted on May 20th 2022, with a recent edit taking place October 27th of the same year. 150 patients are needed to be recruited from 6 separate sites."
How many sites are participating in the execution of this clinical trial?
"This clinical trial is conveniently located at Honorhealth in Atlanta, Georgia, Emory Winship Cancer Institute in Indianapolis, Indiana and the Melvin and Bren Simon Comprehensive Cancer Center of Indiana University in San Antonio Texas. Additionally, it can be found at 6 other sites throughout the country."
How many people have opted in to participate in this medical experiment?
"150 suitable volunteers are necessary for successful completion of the trial. These participants can be recruited from Honourhealth in Atlanta, Georgia and Emory Winship Cancer Institute located in Indianapolis, Indiana."
Who else is applying?
What state do they live in?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger